Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Property, Plant & Equipment (Net)
Physical long-term assets such as land, buildings, and machinery, net of accumulated depreciation.
Mereo BioPharma Group plcNASDAQ: MREO
Property, Plant & Equipment (Net) · Q1 FY2026 · quarter ended Mar 2026
Property, plant & equipment (net) falls 77.1% from a year ago
Property, plant & equipment (net) stood at $199K at the end of Q1 FY2026, down 77.1% from a year earlier and down 47.8% from the prior quarter. Over 3 fiscal years it compounded at -44.4% a year.
Context
- Property, plant & equipment (net) amounted to 0.5% of total assets at the end of Q1 FY2026, down 0.8 pp from a year earlier.
- Property, plant & equipment (net) increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether property, plant & equipment (net) keeps falling in the next quarterly balance sheet after a -77.1% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Property, Plant & Equipment (Net) history
USD · from the balance sheet
- Latest · FY2025
- 381K USD
- Year-over-year change
- -61.3%
- 4-year CAGR
- -42.2%
| Period | Period end | Property, Plant & Equipment (Net) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 381K | -61.3% |
| FY2024 | 2024-12-31 | 984K | -40.4% |
| FY2023 | 2023-12-31 | 1.65M | -25.5% |
| FY2022 | 2022-12-31 | 2.22M | -35.2% |
| FY2021 | 2021-12-31 | 3.42M | — |
Property, Plant & Equipment (Net) vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so property, plant & equipment (net) is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of -77.1% is the lowest of 11, against a peer median of -2.0%.
- Property, plant & equipment (net) amounts to 0.5% of total assets for MREO, versus a peer median of 3.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $41.66M USD | +473.7% | +38.2% | 12.8% | |
| Mar 2026 | €12.06M EUR | -17.9% | -8.1% | 12.2% | |
| Mar 2026 | $9.73M USD | +10.6% | -24.2% | 3.8% | |
LXEOLexeo Therapeutics, Inc. Common Stock | Mar 2026 | $8.35M USD | -17.6% | -13.7% | 3.3% |
CTNMContineum Therapeutics, Inc. Class A Common Stock | Mar 2026 | $8.07M USD | +31.8% | +58.8% | 3.1% |
| Mar 2026 | CHF 6.37M CHF | -19.9% | -2.6% | 4.6% | |
| Mar 2026 | $3.64M USD | +49.8% | — | 1.8% | |
| Mar 2026 | $1.54M USD | -14.6% | -7.4% | 1.3% | |
| Dec 2025 | A$1.32M AUD | +94.1% | +22.7% | 0.9% | |
| Mar 2026 | $209.26K USD | -55.2% | +0.9% | 0.3% | |
| Mar 2026 | $199K USD | -77.1% | -44.4% | 0.5% | |
| Peer median (excluding MREO) | — | -2.0% | -2.6% | 3.2% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 126.75M | 68.18M | 57.42M | 69.8M | 40.99M |
| Short-term Investments | 769.47K | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 3.73M | 3.25M | 1.98M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 3.01M | 3.23M | 1.98M | 507K | 141K |
| Total Current Assets | 134.32M | 75.2M | 63.76M | 74.76M | 45.02M |
| Property, Plant & Equipment (Net) | 3.42M | 2.22M | 1.65M | 984K | 381K |
| Goodwill | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 33.22M | 29.01M | 1.09M | 643K | 516K |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 1 | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 36.64M | 2.22M | 2.74M | 1.63M | 897K |
| Total Assets | 170.96M | 77.41M | 66.5M | 76.39M | 45.92M |
| Account Payables | 3.09M | 3.49M | 2.35M | 2.44M | 1.33M |
| Short-term Debt | 0 | 13.33M | 0 | 5.54M | 0 |
| Tax Payables | 0 | 0 | 662K | 770K | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 7.6M | 1.36M | 2.37M | (413K) | 1M |
| Total Current Liabilities | 16.96M | 24.38M | 9.49M | 13.85M | 4.3M |
| Long-term Debt | 19.45M | 0 | 4.39M | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 13.17M | 157K | 1.18M | 1.39M | 699K |
| Total Non-current Liabilities | 34.99M | 1.64M | 6.48M | 1.57M | 699K |
| Total Liabilities | 51.95M | 26.01M | 15.96M | 15.42M | 5M |
| Common Stock | 2.37M | 2.48M | 2.78M | 3.06M | 3.14M |
| Retained Earnings | (401.6M) | (404.58M) | (419.63M) | (462.88M) | (501.02M) |
| Accumulated OCI | 183.58M | (21.69M) | (17.49M) | (18.85M) | (10.82M) |
| Other Stockholders Equity | 1 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 119.01M | 51.4M | 50.54M | 60.97M | 40.92M |
| Total Debt | 22.66M | 15.37M | 5.95M | 6.43M | 202K |
| Net Debt | (104.08M) | (52.81M) | (51.47M) | (63.37M) | (40.79M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.